Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 3/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185402 | 0.83 | GPR84 (0.48) | ESR1ESR2EGFR | |
| SCHEMBL2185142 | 0.83 | KDM2B (0.51) | XDHSLC22A12 | |
| SCHEMBL27627326 | 0.81 | ESR2 (0.73) | ESR1ESR2 | |
| SCHEMBL19919240 | 0.81 | ESR1 (0.49) | ESR1ESR2 | |
| SCHEMBL2185427 | 0.79 | KDM4C (0.49) | XDH | |
| SCHEMBL2186006 | 0.77 | ESRRB (0.55) | ESR1ESR2 | |
| SCHEMBL12317044 | 0.76 | KDM2B (0.39) | XDHSLC22A12 | |
| SCHEMBL12317045 | 0.76 | XDH (0.39) | ESR1ESR2XDHSLC22A12 | |
| SCHEMBL2051393 | 0.76 | XDH (0.50) | XDHRXRARXRB | |
| SCHEMBL31525283 | 0.75 | PTPN1 (0.60) | SLC22A12ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343279-B1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-8263622-B2 | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263622-B2 | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263622-B2 | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2343279-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343279-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010044405-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | キッセイ薬品工業株式会社 (JP) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | XDH, OAT, PON1 | ESR1 3404/4885ESR2 2417/4885EGFR 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.